Apogee Therapeutics, Inc. (APGE) Dividend History

Company News

• Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

  Apogee Therapeutics announced positive interim results from a Phase 1b trial of its novel antibody APG808 in patients with mild-to-moderate asthma, showing rapid and sustained suppression of a biomarker of inflammation and a favorable safety profile.

  GlobeNewswire Inc.
• Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

  Apogee Therapeutics announced progress in its Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule. The company also reported positive interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, which exceeded trial objectives and demonstrated an approximately 60-day half-life.

  GlobeNewswire Inc.
• Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

  Apogee Therapeutics announced positive interim Phase 1 results for its novel antibody APG990, which demonstrated a long half-life of around 60 days, supporting potential for infrequent dosing. The company plans to initiate a Phase 1b trial of the APG990 and APG777 combination (APG279) against DUPIXENT in 2025.

  GlobeNewswire Inc.
• Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

  Apogee Therapeutics announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis. The Part A portion of the trial exceeded enrollment targets, and the company plans to advance APG777 into additional indications.

  GlobeNewswire Inc.
• Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

  Apogee Therapeutics provided updates on its pipeline, including positive interim Phase 1 data for APG808, long-term data for APG777 supporting potential for annual dosing, and plans for combination trials in atopic dermatitis, asthma, and COPD.

  GlobeNewswire Inc.